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A B S T R A C T
The present studies were conducted to changes arising from mercury poisoning in the central nervous
system (CNS), with a focus on determining the receptors and neurotransmitters involved. Currently,
little is known regarding the neurological basis of the cardiopulmonary effects of mercury poisoning.We
evaluated changes in systolic arterial pressure (SAP), diastolic arterial pressure (DAP), respiratory rate
(RR) and heart rate (HR) following a 5 ml intracisternal (i.c) injection ofmercuric chloride (HgCl2) and the
participation of the autonomic nervous system in these responses. 58 animals were utilized and
distributed randomly into 10 groups and administered a 5 mL intracisternal injection of 0.68 mg/kg
HgCl2 (n = 7), 1.2 mg/kg HgCl2 (n = 7), 2.4 mg/kg HgCl2 (n = 7), 60 mg/kg HgCl2 (n = 7), 120 mg/kg HgCl2
(n = 3), saline (control) (n = 7), 60 mg/kg HgCl2 plus prazosin (n = 6), saline plus prazosin (n = 6), 60 mg/kg
HgCl2 plus metilatropina (n = 4) or saline plus metilatropina (n = 4)HgCl2. Anesthesia was induced with
halothane and maintained as needed with urethane (1.2 g/kg) administered intravenously (i.v.) through
a cannula placed in the left femoral vein. The left femoral artery was also cannulated to record systolic
arterial pressure (SAP), diastolic arterial pressure (DAP) and heart rate (HR). A tracheotomy was
performed to record respiratory rate. Animals were placed in a stereotaxic frame, and the cisternamagna
was exposed. After a stabilization period, solutions (saline or HgCl2) were injected i.c., and
cardiopulmonary responses were recorded for 50 min. Involvement of the autonomic nervous system
was assessed through the i.v. injection of hexamethonium (20 mg/kg), prazosin (1 mg/kg) and
methylatropine (1 mg/kg) 10 min before the i.c. injection of HgCl2 or saline. Treatment with 0.68, 1.2,
2.4 mg/kg HgCl2 or saline did not modify basal cardiorespiratory parameters, whereas the 120 mg/kg
dose induced acute toxicity, provoking respiratory arrest and death. The administration of 60 mg/kg
HgCl2, however, induced signiﬁcant increases (p < 0.05) in SAP at the 308, 408 and 508 min, timepoints
and DAP at the 58, 108, 208, 308, 408 and 508 timepoints. RR was signiﬁcantly decreased at the 58, 108, 208,
408 and 508 min timepoints; however, there was no change in HR. Hexamethonium administration,
which causes non-speciﬁc inhibition of the autonomic nervous system, abolished the observed
cardiorespiratory effects. Similarly, prazosin, a a1-adrenoceptor blocker that speciﬁcally inhibits
sympathetic nervous system function, abolished HgCl2 induced increases in SAP and DAP without
affecting HR and RR. Methylatropine (1 mg/Kg), a parasympathetic nervous system inhibitor,
exacerbated the effects of HgCl2 and caused slow-onset respiratory depression, culminating in
respiratory arrest and death. Our results demonstrate that increases in SAP and DAP induced by the i.c.
injection of mercuric chloride are mediated by activation of the sympathetic nervous system.
 2011 Elsevier Inc. Open access under the Elsevier OA license.
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Due to its toxicity and mobility in ecosystems, mercury is
considered to be an environmental pollutant that poses a high
health risk (Davis et al., 1994). Ingestion or inhalation ofmercury is
known to induce toxicity in a number of different biological
systems, including the heart, lung, kidney, brain and immune
system (Oliveira et al., 1994; Houser et al., 1992; Go´mez et al.,
2007; Gleichmann et al., 1989). In Iraq, the ingestion of breadmade
B.F. Azevedo et al. / NeuroToxicology 32 (2011) 350–354 351with mercury-contaminated wheat resulted in the deaths of over
500 people (Bakir et al., 1973). Similar cases of mercury poisoning
due the ingestion of contaminated wheat have been reported in
Pakistan (1963), Guatemala (1966), Argentina (1980) and New
Mexico (Bakir et al., 1973; Clarkson, 1993; Saint-Phard and Van
Dorsten, 2004).
Mercury is highly neurotoxic (Bakir et al., 1973; Gochfeld,
2003). Patients in Japan and Iraq suffering frommercury poisoning
presented with symptoms of neural dysfunction, including ataxia,
the deterioration of speech, decreased in the visual ﬁeld, sensory
changes, deafness, blindness, tremors, involuntary movements,
mental retardation, coma and death. These clinical symptoms of
mercury poisoning have been described as Minamata disease and
Hunter–Russell syndrome (Gochfeld, 2003; Takeuchi et al., 1996).
Currently, studies on theeffectsofmercury in the centralnervous
system (CNS) focus on determining which neurotransmitters and
receptorsare involved in theneurotoxicityofmercury.Despite these
efforts, much remains unknown, particularly with regard to
cardiopulmonary effects induced by mercury poisoning (Cao
et al., 2010; Atchison and Narahashi, 1982; Atchison, 1986; Shafer
et al., 1990). This study was designed to evaluate the mercury dose
could alter the neural regulation of cardiorespiratory system when
used acutely in central nervous systemanddetermine the role of the
autonomic nervous system in this process.
2. Materials and methods
Male Wistar rats weighing 300 g were used for this study. All
experiments were conducted in compliance with the guidelines for
biomedical research provided by the Brazilian Societies of Experi-
mental Biology and approved by the Institutional Ethics Committee
(CEUA-EMESCAM 003 and 021/2007). The animals were housed
under standard laboratory conditionswithwater and food provided
ad libitum,andenvironmental temperaturewas set at26  2 8C.Rats
were anesthetized with vaporized halothane gas (3%) in an induction
chamber and maintained under anesthesia with intravenous (i.v.)
administration of urethane (1.2 g/kg). Supplementary doses of
anesthetic were administered when necessary, as indicated by the
paw pinch reﬂex and/or by unstable cardiovascular recordings. For i.v.
drug administration, the left femoral vein was cannulated with a
heparinized (40 U/ml) catheter (PE 50) ﬁlledwith saline. Arterial blood
pressure was recorded using a heparinized (40 U/ml) saline-ﬁlled
catheter (PE50) inserted into the left femoral artery and connected to a
pressure transducer (Statham P23 Db, Valley View, OH, USA). Systolic
arterial pressure (SAP), diastolic arterial pressure (DAP) and heart rate
(HR) were recorded with a Gould RS 3400 polygraph. A tracheotomya b
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Fig. 1. (A) Systolic arterial pressure (SAP) and (B) diastolic arterial pressure (DAP) in con
expressed as the mean  SEM. Two-way ANOVA, repeated measures. p < 0.05: *control (was performed on all animals, and the respiratory rate (RR) was
recorded using a pneumotachograph (Fleish 0000) and a low-pressure
transducer (Valadine) connected to a polygraph. All cardiovascular and
respiratoryactivitydataweredigitalized (BiopacMP100)andstoredon
a computer hard drive prior to analysis. A homeothermic blanket
(Harvard) was used to maintain rectal temperatures between 36 and
37 8C.
Animals were mounted on a stereotaxic apparatus (Stoelting,
Wood Dale, IL, USA) to provide stabilization and bilateral
symmetry of the skull. The lifting bar was placed in the ear, and
the external auditory canal incisive barrier was set at11 mm. For
intracisternal (i.c.) injections, the dorsal surface of the brainstem
was exposed by retracting the skin and muscles at the base of the
skull, allowing visualization of the atlanto-occipital membrane.
Mercuric chloride (HgCl2) injections were performed with a Mizzi
needle inserted into the cisterna magna. The Mizzi needle was
connected to a microsyringe (Hamilton, 10 mL) and a polyethylene
(PE 10) catheter ﬁlled with the injection solution.
58 animals were utilized and distributed randomly into 10
groups and administered a 5mL intracisternal injection of 0.68mg/
kg HgCl2 (n = 7), 1.2 mg/kg HgCl2 (n = 7), 2.4 mg/kg HgCl2 (n = 7),
60 mg/kg HgCl2 (n = 7), 120mg/kg HgCl2 (n = 3), saline (control)
(n = 7), 60mg/kg HgCl2 plus prazosin (n = 6), saline plus prazosin
(n = 6), 60mg/kg HgCl2 plus metilatropina (n = 4) or saline plus
metilatropina (n = 4). Data recordings began after hemodynamic
stabilization was achieved. All microinjections were performed at
the after 0 timepoint, after baseline recordings were obtained. SAP,
DAP, HR and RRwere recorded at the following timepoints: 0 (prior
to i.c. injection) and 5, 10, 20, 30, 40 and 50 min injection of HgCl2
or saline. To evaluate the involvement of the autonomic nervous
system in cardiorespiratory responses to mercury, animals were
also administered the following drugs: hexamethonium (20 mg/
kg, i.v), a ganglionic blocker that causes non-speciﬁc inhibition of
the autonomic nervous system; prazosin (1 mg/kg, i.v), an a1-
receptor blocker that inhibits only the sympathetic branch of the
autonomic nervous system; and methylatropine (1 mg/kg, i.v), a
cholinergic blocker that inhibits only the parasympathetic branch
of the autonomic nervous system. The effect of these drugs on basal
cardiorespiratory regulation was assessed before and 10 min after
their injections. Data were collected at the following timepoints: 0
(stabilization), 10 min after administering hexamethonium/
methylatropine/prazosin and 5, 10, 20, 30, 40 and 50 min after
injection of HgCl2 or saline.
Data are presented as the mean  SEM. The two-way ANOVA
analysis followed by post hoc Bonferroni tests. Signiﬁcance was
assumed at p < 0.05.140
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trol and 60 mg/kg HgCl2-treated animals before and after i.c. injection. Results are
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Fig. 2. (A) Heart rate (HR) and (B) respiratory rate (RR) in control (n = 7) and 60 mg/kg HgCl2-treated (n = 7) animals before and after i.c. injection. Results are expressed as the
mean  SEM. Two-way ANOVA, repeated measures. p < 0.05: *control vs. HgCl2-treated rats; #before vs. after HgCl2 treatment.
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Treatment with 0.68, 1.2, and 2.4mg/kg HgCl2 or saline did not
modify basal cardiorespiratory parameters, whereas 120mg/kg
HgCl2 induced acute toxicity, resulting in respiratory arrest and
death. Microinjection of 60 mg/kg HgCl2, on the other hand,
induced a signiﬁcant increase (p < 0.05) in SAP and DAP while
reducing the RR (Figs. 1A, B and 2B).
To determine the role of the autonomic nervous system in these
cardiopulmonary changes, hexamethonium (20 mg/kg, i.v.), a
ganglionic blocker, was administered. Hexamethonium induced
similar decreases in SAP, DAP, HR and RR in both control and
experimental groups and resulted in the reversal of several
cardiorespiratory effects observed in animals treated with 60 mg/
kg HgCl2 (see Table 1).
The autonomic nervous system is composed of two subsystems:
the sympathetic and parasympathetic nervous systems. We
further elucidated the role of the autonomic nervous systemFig. 3. (A) Systolic arterial pressure (SAP) and (B) diastolic arterial pressure (DAP) in con
and administration of the a1-receptor blocker, prozasin. Results are expressed as the m
rats; #before vs. after HgCl2 treatment.
Table 1
Effect of administration of hexamethonium in control and mercury (60mg/kg) groups.
Star Hexa 5min
SAP (mmHg) Ct 1253§ 871 922
HgCl2 1253§ 805 896
DAP (mmHg) Ct 845§ 653 673
HgCl2 883§ 574 655
HR (bpm) Ct 39915§ 3697 3778
HgCl2 41017§ 37817 37717
RR (breaths/min) Ct 1045§ 11810 1127
HgCl2 1025§ 11512 11211
Systolic arterial pressure (SAP), diastolic arterial pressure (DAP), heart rate (HR), respirat
as mean SEM. 2-way ANOVA followed by Bonferroni post-tests for all analysis. Ct (n =
treatment.: /before vs. after hexametoˆnio.using prazosin, a a1-adrenergic antagonist that inhibits sympa-
thetic function, and methylatropine, a cholinergic receptor blocker
that inhibits parasympathetic function. Prasozin partially abol-
ished the effects of HgCl2 on SAP, DAP, RR and increased the HR
(Figs. 3A, B and 4A, B). Methylatropine (1 mg/kg, i.v.), however,
exacerbated the cardiorespiratory effects of HgCl2, causing slow-
onset respiratory depression that culminated in respiratory arrest
and death.
4. Discussion
The present study demonstrates that HgCl2 induces changes in
the cardiorespiratory regulation, characterized primarily by
increases in SAP and DAP and reduced RR. Furthermore, our
results elucidate the role of the autonomic nervous system in these
responses autonomic blockade abolished hemodynamic and RR
changes. Our use of i.c. microinjections allows substances to access
various sites in the dorsal and ventral surfaces of the medullatrol (n = 6) and 60mg/kg HgCl2-treated (n = 6) animals before and after i.c. injection
ean  SEM. Two-way ANOVA, repeated measures. p < 0.05: *control vs. HgCl2-treated
10min 20min 30min 40min 50min
903 923 945 952 953
945 913 1009 1029 10710
672 662 683 754 714
674 644 635 656 676
37313 37612 38115 38518 38921
37917 38317 39120 40020 39622
10210 1039 1048 11510 1139
1109 1125 1084 1178 1108
ory rate (RR) of control rats (CT) and mercury rats (HgCl2). The results are expressed
6) vs. HgCl2 (n =6). p< 0.05: *control vs. HgCl2-treated rats;
#before vs. after HgCl2
Fig. 4. (A) Heart rate (HR) and (B) respiratory rate (RR) in control (n = 6) and 60mg/kg HgCl2-treated (n = 6) animals before and after i.c. injection and administration of thea1-
receptor blocker, prazosin. The results are expressed as the mean  SEM. Two-way ANOVA, repeated measures. p < 0.05: *control vs. HgCl2-treated rats; #before vs. after HgCl2
treatment.
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surface areas are involved in various mechanisms of central
autonomic and respiratory regulation. It is likely that the observed
changes in cardiorespiratory regulation are the consequence of
HgCl2 toxicity in these areas; however, the present technique is
unable to conﬁrm the precise brain regions targeted.
The present study was aimed to evaluate the effects of
intracisternal injection of HgCl2 in the central control of
cardiovascular and respiratory systems, given that our discussion
will be made through hypotheses that justify the changes in the
central control of cardiovascular and respiratory systems.
The doses of 0.68, 1.2, and 2.4 mg/kg HgCl2 were not able to
cause cardiovascular and respiratory changes when injected into
the CNS, considering this, we have studied the doses with little or
no neurotoxic effect.
It is possible that the observed increases in SAP and DAP
induced by the injection of 60 mg/kg HgCl2 are due to inhibition of
glutamate uptake by the rostral ventrolateral medulla (RVLM).
This would result in extended RVLM stimulation causing an
increase in sympathetic activity that, in turn, increases SAP and
DAP. Indeed, Brookes (1992) and Aschner et al. (2000) reported
that methylmercury inhibits glutamate uptake, increasing glu-
tamatergic stimulation of the CNS that can result in cell death and
neurodegeneration. Alternatively, inhibition of the nucleus of the
solitary tract (NTS) through GABA receptor stimulation would
result in Gi-protein activation and the opening of chloride ion
channels. These changes would lead to inhibition of the caudal
ventrolateral medulla (CVLM) and RVLM activation. Huang and
Narahash (1996) demonstrated that mercury can bind to
sulhydryl groups in dorsal root ganglion neurons, resulting in
the activation of Gi proteins and the opening of chloride ion
channels.
In addition to the effects on SAP and DAP, we observed
signiﬁcant reductions in RR (Fig. 4) following i.c. treatment with
HgCl2. This could be mediated through direct neurotoxicity or cell
death indirectly induced by glutamate overstimulation in the
nucleus ambiguus (NA), a region that contains pre-respiratory
motoneurons (Von Euler, 1979). On the other hand, the hyperpo-
larization of NTS through chloride ion channel activation could
result from GABA receptor activation which inhibits NA activity,
causing a reduction in the respiratory rate. When stimulated, the
NA can promote both bradycardia and tachycardia, depending on
the receptor type that is activated. Studies in cats have shown that
microinjection of L-glutamate within subregions of the NA
promoted intense bradycardia (Massari et al., 1995; Gatti et al.,
1996). Conversely, Chistravanshi et al. (1991) demonstrated that
microinjection of glycine into the NA elicited tachycardia. It is
possible that HgCl2 interacts with both NA receptor types, thus
resulting in a null effect on HR.
Based on these ﬁndings it was necessary to evaluate the
participation of the autonomic nervous system in the cardiore-spiratory changes induced by the i.c. injection of 60 mg/kg HgCl2.
Hexamethonium, a ganglion blocker, reversed the cardiopulmo-
nary effects triggered by 60 mg/kg HgCl2 (Table 1), thus
conﬁrming the involvement of the autonomic nervous system
as a mediator of cardiorespiratory responses. Hexamethonium,
however, affects both the sympathetic and parasympathetic
branches of the autonomic nervous system, thus preventing
determination of the speciﬁc subsystem mediated the observed
changes. We evaluated the role of the parasympathetic subsys-
tem using methylatropine a muscarinic acetylcholine receptor
antagonist. Vassallo et al. (1996) observed that atropine
prolonged the survival of animals from 60 to 120 min following
an i.v. injection of high concentrations of HgCl2. In the present
study, all animals treated with methylatropine after i.c. HgCl2
microinjection exhibited respiratory arrest and death. Although
methylatropine does not cross the blood–brain barrier, it is
absent in certain areas of the medulla. These areas are the
putative sites of action for this anti-muscarinic drug. Inhibition of
acetylcholine in these areas of the medulla would likely
exacerbate HgCl2 toxicity, explaining the observed respiratory
arrest and death. It is important to note, however, that the current
results do not conﬁrm this hypothesis. To evaluate the role of the
sympathetic nervous system, prazosin, an a1-receptor antago-
nist, was used. The blockage ofa1-receptors reversed the changes
triggered by 60 mg/kg HgCl2. These results indicate that the
effects of HgCl2 on cardiopulmonary regulation are likely driven
by the sympathetic nervous system.
The present study suggest that 60 mg/kg HgCl2 elicits a
signiﬁcant increase of SAP, DAP and reduced RR and that these
effects are likely mediated through the activation of the
sympathetic nervous system.
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